Hand sanitation monitoring system provider SwipeSense has secured $10.6m to expand its team and accelerate product development.

Gilead, Boehring Ingelheim and Takeda have contributed to a $59.6m round for Hookipa, a developer of immunotherapies for infectious diseases and cancer.

Alexandria Venture Investments has participated in an NEA-led round that took the total raised by the metabolic disease drug startup to $60m.

The firm, formed by the merger of WuXi Healthcare Ventures and Frontline Bioventures, is raising a $26m affiliates fund according to a securities filing.

The transaction includes a 12.2% stake in Cell Design held by Kite Pharma, which Gilead bought for $11.9bn in October this year.

Adding Cell Design and Kite Pharma to its portfolio brings Gilead to the top table in probably the hottest area for advanced therapies and follows the playbook the company has used over the past few decades to expand.

Dalian Yifang Group has contributed to a $30.2m series B round for Etong, which will use the funding to expand its customised checkup services.

Medical device maker Edwards Lifesciences has acquired cardiovascular device developer and University of Maryland, Baltimore spinout Harpoon Medical.

VC fund manager AmorChem has launched AmorChem II, a $44.2m seed-stage life sciences fund backed by Merck & Co.